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Introduction Systemic sclerosis (SSc)-related
pulmonary arterial hypertension (PAH) has emerged as a
major mortality prognostic factor. Mutations of
transforming growth factor beta (TGFβ) receptor
genes strongly contribute to idiopathic and
familial PAH.
Objective To explore the genetic bases of SSc–PAH,
we combined direct sequencing and genotyping of
candidate genes encoding TGFβ receptor family
members.
Materials and methods TGFβ receptor genes,
BMPR2, ALK1, TGFR2 and ENG, were sequenced in 10
SSc–PAH patients, nine SSc and seven controls. In
addition, 22 single-nucleotide polymorphisms (SNP) of
these four candidate genes were tested for association in
a first set of 824 French Caucasian SSc patients
(including 54 SSc–PAH) and 939 controls. The replication
set consisted of 1516 European SSc (including 219 SSc–
PAH) and 3129 controls from the European League
Against Rheumatism Scleroderma Trials and Research
group network.
Results No mutation was identified by direct
sequencing. However, two repertoried SNP, ENG
rs35400405 and ALK1 rs2277382, were found in
SSc–PAH patients only. The genotyping of 22 SNP
including the latter showed that only rs2277382 was
associated with SSc–PAH (p=0.0066, OR 2.13, 95% CI
1.24 to 3.65). Nevertheless, this was not replicated with
the following result in combined analysis: p=0.123, OR
0.79, 95% CI 0.59 to 1.07.
Conclusions This study demonstrates the lack of
association between these TGFβ receptor gene
polymorphisms and SSc–PAH using both sequencing and
genotyping methods.
INTRODUCTION
Systemic sclerosis (SSc) is characterised by major
vascular involvement. Pulmonary arterial hyperten-
sion (PAH) is currently an important challenge in
SSc and given the severity of this condition and the
poor understanding of its risk factors and pathogen-
esis, there is an urgent need to identify novel risk
factors for the development of SSc–PAH.1 The iden-
tification of mutations in the BMPR2 gene, and also
in other transforming growth factor beta (TGFβ)
receptor genes in idiopathic PAH and familial PAH
has been an important step forward. Indeed, muta-
tions in the BMPR2 gene, which encodes a type II
bone morphogenetic protein receptor of the TGFβ
cell signalling superfamily, underlie the majority of
hereditary PAH cases2 but have also been identified
in other disease subtypes including idiopathic PAH
and PAH associated with other disorders.3 4
Mutations in two further receptor members of the
TGFβ signalling superfamily have been identified as
uncommon causes of hereditary PAH. Indeed, her-
editary haemorrhagic telangiectasia (HHT) is an
autosomal dominant vascular disease, caused by
heterozygous mutations of either TGFβ type I
receptor activin-like kinase-type 1 (ALK1) or of the
endoglin gene (ENG).5 A small proportion of HHT
patients have PAH that is clinically and histopatho-
logically indistinguishable from other heritable
forms of PAH. In rare cases, mutations of ALK-1
appeared to cause idiopathic PAH and hereditary
PAH without HHT.4 Therefore, BMPR2, ALK1 and
ENG genes, belonging to the TGFβ superfamily,
represent good candidates for the study of genetic
susceptibility to SSc–PAH.
Few studies have attempted to identify SSc–PAH
genetic risk factors. Despite some relevant prelimin-
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ary results, a lack of appropriate cohorts (because of imperfect
phenotype and/or insufficient statistical power) has precluded
definite conclusions.6–9
The aim of this study was to investigate a specific genetic
basis favouring the occurrence of PAH in SSc, using a synergistic
strategy combining direct sequencing together with genotyping
of common variants of candidate genes encoding four TGFβ
receptors: BMPR2, ALK1, ENG and TGFBR2.
PATIENTS AND METHODS
Study population
All SSc patients and controls were of European Caucasian
origin and were provided through the European League Against
Rheumatism Scleroderma Trials and Research group (EUSTAR)
centres. The discovery set consisted of 824 SSc patients, includ-
ing 54 SSc–PAH patients and 939 controls from French centres.
The replication set consisted of cohorts from other French
centres (175 SSc patients including 75 SSc–PAH patients and
438 controls), northern/central Europe (455 SSc, 59 SSc–PAH
and 1823 controls), Italy (542 SSc, 33 PAH–SSc and 479 con-
trols) and eastern Europe (344 SSc, 52 SSc–PAH and 389 con-
trols). The characteristics of the study population have been
detailed previously.10 Clinical data collected included age, sex,
disease duration and cutaneous SSc subtypes according to the
definition of Leroy et al.11 Precapillary PAH diagnosis was estab-
lished following right heart catheterisation as recommended.12
All local institutional review boards approved the study, and
written informed consent was obtained from all study subjects.
Direct sequencing
As a first approach, 26 French Caucasian individuals (10 SSc–PAH
patients, nine SSc patients without PAH and seven healthy
controls) were sequenced for the candidate genes encoding four
TGFβ receptors: BMPR2, ENG, ALK1 and TGFBR2. Genomic
DNA was extracted from blood samples (Qiagen, Courtaboeuf,
France). PCR primers were designed using Primer 3 to amplify
segments of genomic DNA that included the exons and intron–
exon boundaries to detect splice-site variants. PCR products were
purified using ExoSAP-IT (USB Corp., Cleveland, Ohio, USA) and
sequenced using the BigDye Terminator V.3.1 cycle sequencing kit
(Applied Biosystems, Foster City, California, USA).
Genotyping
As a second approach, any single-nucleotide variation detected
by direct sequencing in SSc–PAH patients and not present
either in controls or PAH-free SSc patients, was tested for asso-
ciation in the genotyping cohort. In addition, Tag single-
nucleotide polymorphisms (SNP) with a minor allele frequency
(MAF) greater than 5% were genotyped for each of the four
TGFβ receptor genes using the KASpar genotyping system
(KBioscience, Hoddesdon, UK) as previously described.13 Six
SNP of the BMPR2 gene (rs7600694, rs1061157, rs1048829,
rs6747756, rs1980153, rs16839127), seven SNP of the TGFBR2
gene (rs377626, rs1841528, rs2372092, rs3773661, rs9867701,
rs11466531, rs11466536), four SNP of the ALK1 gene (rs706815,
rs772003, rs2277382, rs3782479) and five SNP of the ENG gene
(rs35400405, rs1998923, rs1330684, rs10987746, rs17557600)
were chosen according to linkage disequilibrium structure. The
average genotype completeness for these variants was above
97% for both the SSc and the control samples.
Statistical analyses
Statistical analyses were performed as previously described.13
The Bonferroni correction was applied for all tests performed
for SNP marker association with the disease (p value multiplied
by n SNP). The analysis of combined data was performed by
calculation of the pooled OR under a fixed-effects model
(Mantel–Haenszel meta-analysis). No power calculation can be
provided for mutation investigations, but regarding common
SNP (MAF >5%) and for ALK1 rs2277382 in particular, the
combined sample provides a power of 99.9% to detect an asso-
ciation with SSc and of 52.3% for the SSc–PAH subset, with an
OR of 1.5.
RESULTS
Sequencing of TGFβR genes in cases and controls
No mutation was identified through the sequencing of 38 SSc
and 14 control chromosomes (table 1). We identified 17 poly-
morphisms: 13 SNP listed in public databases and four variants
not yet repertoried, none of which were mutations as they
were found both in patients and controls. Two variants
emerged as interesting candidates for further study. Indeed, the
SNP located at codon 14 of exon 1 in the ENG gene, known as
Table 1 Variants identified by direct sequencing of the ENG, ALK1, TGBR2 and BMPR2 genes
Gene Location Nucleotide change Amino acid change rs number MAF SSc–PAH (n=10) SSc without PAH (n=9) Controls (n=7)
ENG Exon 1 c.14 G>A p.T5M rs35400405 NA 3 0 0
Intron 1 (−215) T>C rs60683420 NA 0 2 0
Exon 2 c.227 C>T p.L69L rs16930129 0.165 2 4 2
Intron 2 (+25) A>C rs7847860 NA 0 0 2
Intron 5* (+59) del G NA NA 1 1 1
Intron 7* (+23) ins TCCCCC NA NA 1 9 4
Exon 8 c.1029 G>A p.H343H rs3739817 0.066 0 5 4
Intron 13 (−72) A>G rs10760503 0.407 3 6 2
ALK1 Promoter (−38) C>T rs2277382 0.075 3 0 0
Intron 3 (+11) T>C rs2071218 NA 7 4 5
Intron 3 (−36)* T>A NA NA 6 5 4
Intron 5 (+44)* A>G NA NA 0 0 4
TGFBR2 Intron 2 (+7) A>G p.N389N rs1155705 0.336 4 5 3
Intron 3 (−4) A>T rs11466512 NA 8 4 4
Exon 4 c.1167 C>T rs2228048 0.027 0 0 1
BMPR2 Intron 6 (−22) del T p.R937R rs11464745 NA 1 2 0
Exon 12 c.2811 G>A rs1061157 0.128 3 2 3
*Novel variants.
ALK1, activin A receptor type II-like 1; BMPR2, BMP receptor type II; ENG, endoglin; MAF, minor allele frequency; NA, not available; PAH, pulmonary arterial hypertension;
SSc, systemic sclerosis; TGFBR2, TGFbeta receptor type II.
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rs35400405, introduces an in-frame ATG sequence downstream
of the usual initiating codon that might result in the loss of
the first amino acids. This variation was detected in SSc–PAH
patients only and none of the controls. The rs2277382 SNP of
the ALK1 gene was found only in three SSc–PAH patients,
none of the PAH-free patients and none of the controls. This
SNP is located in the promoter of the gene, and has previously
been identified as a single-nucleotide variation associated with
HHT.14
Association testing of identified variants and common tag
SNP of the TGFβR genes
Discovery set
We investigated the possible association of polymorphisms in the
ALK1, TGFBR2, BMPR2 and EGN genes with SSc and the SSc–
PAH subtype by genotyping rs35400405, rs2277382 and 20 tag
SNP distributed throughout these genes (table 2). No association
was found with SSc in the discovery set. Genetic association was
solely observed between the SSc–PAH subset and the ALK1
rs2277382 SNP (OR 2.13, 95% CI 1.24 to 3.65, padj= 0.0066).
Replication set
Following the results obtained in the discovery set, we selected
the ALK1 rs2277382 SNP to be investigated in the EUSTAR
replication cohort (table 3). Genotype frequencies of the
rs2277382 variant were in Hardy–Weinberg equilibrium in all
control populations. However, we did not observe any associ-
ation between the rs2277382T allele and either SSc–PAH or the
SSc subset in these replication sets.
Meta-analysis in the European Caucasian population
Meta-analysis of the combined discovery and replication popu-
lations (French, northern European, Italian and eastern
European) including a total of 2340 SSc patients, 273 SSc–PAH
and 4068 controls did not provide evidence for an association
between ALK1 rs2277382 and neither SSc–PAH nor SSc.
DISCUSSION
Genes encoding TGFβ receptors have been identified as major
susceptibility genes in familial and idiopathic forms of PAH.
Understanding the genetic differences between idiopathic PAH
and SSc–PAH, and also between patients with SSc who do and
do not develop PAH, may improve our ability to develop
genetic biomarkers of SSc–PAH. This may help to identify
these patients earlier in the disease course and to risk stratify
patients in order to optimise the management of this devastat-
ing condition.
So far, preliminary studies investigating BMPR2 and ALK1
have failed to identify variants associated with SSc–PAH by a
direct sequencing strategy. However, they were limited by small
sample size and heterogeneous definition of PAH.7–9
Furthermore, an insertion in intron 7 of the ENG gene (6bINS)
was reported to be negatively associated with the occurrence of
SSc–PAH in a previous work from our group in a small cohort
of 280 SSc patients including 29 with PAH and 140 controls.15
However, until now this result has not been replicated in a
larger cohort.
In this study, the ALK1 rs2277382 and ENG rs35400405 SNP
were of particular interest because they were detected only in
SSc–PAH patients by direct sequencing, the hypothesis being
that their minor alleles could be associated with the develop-
ment of PAH in our cohorts. However, no association was
found between these polymorphisms and both the complica-
tion that is SSc–PAH and also SSc. This does not rule out the
possible implication of other TGFβ signalling pathway genes.
Indeed, mutations in the SMAD genes have recently been iden-
tified in PAH patients and could represent another potential
candidate to take into account in the genetics of SSc–PAH in
further studies.16 Furthermore, another limitation may come
from the fact that some SSc patients may develop PAH later
during the course of the disease.
Table 3 Association study of ALK1 rs2277382 with SSc and PAH–SSc
in the second set of European Caucasian populations and combined
analysis including the discovery and replication cohorts
N MAF (%) p Value OR (95% CI)
French replication cohort
SSc 175 8.57 0.410 1.21 (0.77 to 1.90)
PAH–SSc 75 8.67 0.524 1.23 (0.66 to 2.29)
Controls 438 7.19 NA NA
Italians
SSc 542 8.76 0.870 1.03 (0.75 to 1.40)
PAH–SSc 33 9.09 0.881 1.07 (0.45 to 2.55)
Controls 479 8.56 NA NA
Northern European
SSc 455 8.46 0.990 0.10 (0.77 to 1.30)
PAH–SSc 59 11.02 0.331 1.34 (0.74 to 2.41)
Controls 1823 8.48 NA NA
Eastern European
SSc 344 5.96 0.570 0.89 (0.58 to 1.35)
PAH–SSc 52 2.88 0.132 0.42 (0.13 to 1.35)
Controls 389 6.68 NA NA
Meta-analysis in the combined discovery and replication populations in an additive
model
SSc 2340 8.44 0.149 0.91 (0.80 to 1.04)
PAH–SSc 273 9.52 0.123 0.79 (0.59 to 1.07)
Controls 4068 7.72 NA NA
Northern European: Germany and Poland; Eastern European: Greece, Hungary,
Romania, Serbia.
MAF, minor allele frequency; NA, not applicable; PAH, pulmonary arterial
hypertension; SSc, systemic sclerosis.
Table 2 Association study of ALK1 rs2277382 and ENG rs35400405 SNP in the French discovery cohort
N MAF (%) Fischer’s p value p-adj* OR (95% CI)
ALK1 rs2277382 SSc 824 9.04 0.003 0.066 1.43 (1.13 to 1.81)
PAH–SSc 54 12.9 0.0003 0.0066 2.13 (1.24 to 3.65)
Controls 939 6.50 NA NA NA
ENG rs35400405 SSc 822 2.49 0.26 NS 1.30 (0.82 to 2.05)
PAH–SSc 54 3.64 0.22 NS 1.92 (0.67 to 5.49)
Controls 906 1.93 NA NA NA
ENG, endoglin gene; MAF, minor allele frequency; NA, not applicable; p-adj*, adjusted p value after Bonferroni correction for multiple SNP testing (n=22); PAH, pulmonary
arterial hypertension; SNP, single-nucleotide polymorphism; SSc, systemic sclerosis.
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In conclusion, this study was conducted using a synergistic
strategy combining direct sequencing for the identification of
potential mutations or rare variants, and genotyping of
common variants in a large sample including a replication step.
These analyses demonstrate the lack of association between
these TGFβ receptor gene polymorphisms and SSc–PAH.
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